articleTop 1% cited

Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*

Critical Care Medicine · 2004 · Vol. 32(1) · pp. 21–30

Ángel Crespo López✉(Hospital Universitario Infanta Cristina)José A. Lorente(Hospital Universitario de Getafe)Jay S. Steingrub(Tufts University)Jan Bakker(Intensive Care Society)Angela McLuckie(Guy's Hospital)Sheila M. Willatts(University Hospitals Bristol NHS Foundation Trust)Michael Brockway(St. Johns Hospital)Antonio AnzuetoLaurent Holzapfel(Servier (France))Desmond P. Breen(Royal Hallamshire Hospital)Michael Silverman(Lakeridge Health)Jukka Takala(University of Eastern Finland)Jill Donaldson(GlaxoSmithKline (Netherlands))Carl Arneson(GlaxoSmithKline (Netherlands))G.Richard Grove(GlaxoSmithKline (Netherlands))Steven H. Grossman(GlaxoSmithKline (Netherlands))Robert F. Grover(GlaxoSmithKline (Netherlands))

View via DOI Publisher page

Abstract

In this study, the nonselective nitric oxide synthase inhibitor 546C88 increased mortality in patients with septic shock.

Nitric Oxide and Endothelin Effects Sepsis Diagnosis and Treatment Cardiac Ischemia and ReperfusionMedicineSeptic shockPlaceboNitric oxide synthaseShock (circulatory)Double blindNitric oxideInternal medicineSepsisPathology

MeSH terms

AdolescentAdultAgedAged, 80 and overCause of DeathCritical CareDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleFollow-Up StudiesHumansIntensive Care UnitsMaleMiddle Aged

Citations

919

FWCI

30.72

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine*